Onco360 Joined Network to Provide Myeloma Drug
Adults with multiple myeloma have a new pharmacy option for accessing the treatment ZENBEXUS.
Updated on Sept. 22, 2026 in Cancer
Bristol-Myers Squibb has selected the specialty pharmacy Onco360 to join the limited distribution network for ZENBEXUS. This medication is indicated for adult patients with multiple myeloma who have received at least one prior line of therapy.
Why it matters
Because ZENBEXUS requires a restricted Risk Evaluation and Mitigation Strategy program due to risks of embryo-fetal toxicity and thromboembolism, access is limited to specifically authorized providers. This expansion in the pharmacy network aims to help patients navigate those specialized safety requirements.
In the EXCALIBER-RRMM clinical trial, researchers evaluated the efficacy of ZENBEXUS in adult patients. The results showed a 41% MRD-negative complete response rate in the treatment arm compared to 21% in the comparator arm.
The players
Onco360
A specialty pharmacy headquartered in Louisville, Kentucky, that provides complex medications.
Bristol-Myers Squibb
A pharmaceutical company based in Princeton, New Jersey, that develops oncology therapies including ZENBEXUS.
The details
ZENBEXUS works by binding to cereblon, a protein that directs the body to break down specific cellular components. This mechanism facilitates the targeted degradation of Aiolos and Ikaros proteins, which are critical for the survival of myeloma cells. Due to the potency of this process and associated safety risks, the drug is dispensed exclusively through a restricted program.
Timeline
2003: Onco360 was founded.
2025: EXCALIBER-RRMM trial results were published.
September 21, 2026: Onco360 selection as a pharmacy provider was announced.
Health Landscape
This development follows the recent dissemination of findings from the EXCALIBER-RRMM trial, which established the clinical efficacy data supporting the current use of this therapy. It reflects a standard trend in oncology where new, highly targeted treatments are tied to restricted pharmacy networks to ensure patient safety.
Patients prescribed ZENBEXUS for multiple myeloma should confirm with their oncology team if their current pharmacy is part of the authorized distribution network. If you are starting this treatment, discuss the safety monitoring requirements of the REMS program with your healthcare provider.
The takeaway
The expansion of pharmacy access is a critical component for patients taking therapies that require stringent safety monitoring. Patients should always coordinate with their hematologist-oncologist to ensure their care team is aligned with the most current distribution channels for their prescription.
Further reading
Learn more about the latest developments in treatment access within the Cancer section.
More information
Find additional details on specialized delivery services by visiting the Onco360 specialty pharmacy information portal.
Source note: This article includes information reported by Firstwordpharma.
